Sobi to present new data in both PNH and ITP at the 2022 EHA congress
Sobi® will present new data at the hybrid EHA (European Haematology Association) congress taking place in Vienna from 9-17 June 2022, highlighting the company’s commitment in rare haematological diseases. Several analyses from the PRINCE phase 3 study with Aspaveli®/Empaveli®(pegcetacoplan) in treatment-naïve patients with paroxysmal nocturnal haemoglobinuria (PNH) will be presented looking at haematologic response and quality of life measures in this patient population, as well as data on D-dimer normalisation and effect on thrombosis following treatment, further building on the safety